南财智讯10月23日电，汉森制药公告，控股股东海南汉森持有的2450万股股份已解除质押，占其所持股 份比例11.56%，占公司总股本比例4.87%。截至公告日，海南汉森累计质押股份1000万股，占其所持股 份比例4.72%，占公司总股本比例1.99%。 ...

证券代码：002412 证券简称：汉森制药 公告编号：2025-020 湖南汉森制药股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 湖南汉森制药股份有限公司（以下简称"公司""本公司"）于近日接到控股股 东海南汉森控股（有限合伙）（以下简称"海南汉森"）通知，获悉海南汉森所持有 本公司的部分股份已办理了解除质押手续，具体事项如下： | 股东 名称 | 是否 为控 股股 东 | 本次解除质 押股份数量 （股） | 占其所 持股份 比例(%) | 占公司 总股本 比例(%) | | 起始日 | | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 海南 汉森 | 是 | 24,500,000 | 11.56 | 4.87 | 2021 21 | 年 6 日 | 月 | 2025年10月 日 22 | 交通银行 股份有限 公司益阳 分行 | | 合计 | - | 24,500,000 | 11.56 | 4.87 ...

10月16日，汉森制药涨0.00%，成交额3333.58万元。两融数据显示，当日汉森制药获融资买入额291.50 万元，融资偿还474.03万元，融资净买入-182.53万元。截至10月16日，汉森制药融资融券余额合计1.51 亿元。 融券方面，汉森制药10月16日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年70%分位水平，处于较高位。 责任编辑：小浪快报 资料显示，湖南汉森制药股份有限公司位于湖南省益阳市赫山区银城大道2688号，成立日期1998年1月 21日，上市日期2010年5月25日，公司主营业务涉及传统中成药制剂、化学药、医用制剂的研发、生产 和销售。主营业务收入构成为：四磨汤口服液54.81%，天麻醒脑胶囊23.38%，缩泉胶囊9.58%，固体口 服制剂5.95%，银杏叶胶囊4.52%，愈伤灵胶囊0.57%，肠胃宁0.52%，液体口服制剂0.34%，利胆止痛胶 囊0.18%，注射剂0.07%，其他0.05%，农产品0.03%。 截至8月29日，汉森制药股东户数2.36万，较上期减少3.43%；人均流通股21113 ...

证券日报网讯汉森制药（002412）9月26日在互动平台回答投资者提问时表示，公司的经营数据等信 息，按照信息披露规则在定期报告中予以披露，具体情况请参考公司发布的公告。 ...

Core Viewpoint - Hansen Pharmaceutical (002412) is currently in the process of scaling up the production technology for its new traditional Chinese medicine product, Cangrong Granules, which is in the pilot study phase [1] Group 1 - The company is actively engaged in product research and development [1] - Cangrong Granules is a new drug derived from traditional Chinese medicine [1] - The product is currently undergoing process pilot testing [1]

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司今年的研发计划里面，创新药占比多少？ 汉森制药（002412.SZ）9月26日在投资者互动平台表示，公司在产品研发方面，中药新药苁蓉颗粒正处 于工艺中试放大研究阶段。具体情况请参考公司2024年度报告。 ...

Group 1 - The core viewpoint of the article is that Hansen Pharmaceutical (002412) acknowledges that the fluctuations in its stock price in the secondary market are influenced by multiple factors, including macro policies, market trends, and investor preferences [1] - The company's management is committed to promoting the company's development and creating value for investors [1]

Core Viewpoint - The performance briefing held by Hunan Hansen Pharmaceutical Co., Ltd. focused on two main issues: the financial loss from investing in Sanxiang Bank and potential acquisition plans for Kangpu Pharmaceutical [1] Group 1: Financial Performance and Strategic Investments - The company acknowledged financial losses due to its investment in Sanxiang Bank, which is part of its "one body, two wings" development strategy aimed at maintaining its core traditional Chinese medicine business while expanding into the health industry and integrating financial services [1] - The company committed to timely information disclosure regarding any significant matters related to the transfer of its stake in Sanxiang Bank [1] Group 2: Potential Mergers and Acquisitions - Investors inquired about the possibility of acquiring Kangpu Pharmaceutical, in which the controlling shareholder Liu Ling'an increased his stake in 2021 [1] - The company stated that it would also disclose any future merger and acquisition activities in a timely manner [1] Group 3: Investor Communication - The performance briefing allowed direct communication between investors and the company's management, highlighting the company's commitment to transparency and timely information disclosure regarding strategic investments and potential acquisitions [1]

Group 1: Company Strategy - The company's main business is traditional Chinese medicine, and it has invested in Sanxiang Bank, which has led to financial losses. The company emphasizes that the investment is part of its "one body, two wings" development strategy, integrating traditional medicine with the health and financial industries [2]. - The company will disclose any significant matters related to the transfer of Sanxiang Bank's equity in a timely manner [2]. Group 2: Future Plans - There is a question regarding whether the company has plans to acquire Kangpu Pharmaceutical after the major shareholder Liu Ling'an increased his stake in 2021. The company stated that any future acquisition matters will also be disclosed promptly [2].

Group 1 - The company Hansen Pharmaceutical (002412) reported that as of August 29, 2025, the total number of shareholders, including those with credit accounts, is 23,580 [1]